Exited position

Stanley Druckenmiller’s Abbott Laboratories (ABT) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Duquesne Family OfficeVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2012Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares1.44MHighest verified quarter-end share count
Quarters reported13Verified quarters with shares above zero
What happened?

Duquesne Family Office first reported Abbott Laboratories in Q1 2012. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Duquesne Family Office sold the entire position in Q2 2020, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2020
Sold the entire position−791.30K shares · No shares reported at quarter-end
Q1 2020
Sold 13.6% of the position−125.00K shares · 791.30K shares remained
Filing context

Quarter-end price $78.91 · Estimated holding basis $73.62

Q2 2019
Sold 36.4% of the position−523.90K shares · 916.30K shares remained
Filing context

Quarter-end price $84.10 · Estimated holding basis $73.62

Q1 2019
Bought 11.2% more+144.50K shares · 1.44M shares reported after the change
Filing context

Quarter-end price $79.94 · Estimated holding basis $73.62

Q4 2018
Bought 77.0% more+563.60K shares · 1.30M shares reported after the change
Filing context

Quarter-end price $72.33 · Estimated holding basis $72.91

Q3 2018
New position+732.10K shares · 732.10K shares reported
Filing context

Quarter-end price $73.36 · Estimated holding basis $73.36

3 unchanged quarters are collapsed by default.

Portfolio importance

How important was Abbott Laboratories in Duquesne Family Office’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight2.5%Q1 2020
Last reported rank#13of 43 reported positions
Peak portfolio weight5.8%Q4 2018
Best historical rank#4Q4 2018
At peak importanceQ4 2018
ABT
5.8%
Largest holding
28.8%
Cross-investor discovery

Who else owns Abbott Laboratories?

Also reported by 4 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
ABT0.1% of reported portfolio
George SorosSoros Fund Management
ABT0.1% of reported portfolio
Ray DalioBridgewater Associates, LP
ABT0.0% of reported portfolio
Explore Abbott Laboratories across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$101.952026-09-11

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.